Drug Profile
Research programme: monoclonal antibody therapeutics - X4 Pharmaceuticals
Alternative Names: ASN 200; ASN 300; ASN 4; ASN 400; ASN 5Latest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Arsanis
- Developer X4 Pharmaceuticals
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Escherichia coli infections; Klebsiella infections; Nosocomial infections; Streptococcal infections
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 24 Aug 2022 Discontinued - Preclinical for Escherichia coli infections (Prevention) in Austria (Parenteral)
- 24 Aug 2022 Discontinued - Preclinical for Escherichia coli infections in Austria (Parenteral)